Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips Sells 26,545 Shares

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock in a transaction on Friday, April 12th. The stock was sold at an average price of $0.86, for a total value of $22,828.70. Following the sale, the chief executive officer now owns 129,726 shares in the company, valued at $111,564.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jack Phillips also recently made the following trade(s):

• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total value of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total value of $642.20.

Accelerate Diagnostics Stock Performance

Accelerate Diagnostics stock traded down $0.08 during midday trading on Wednesday, hitting $0.74. 115,691 shares of the company’s stock were exchanged, compared to its average volume of 120,337. The stock has a 50-day moving average price of $1.02 and a two-hundred day moving average price of $3.23. Accelerate Diagnostics, Inc. has a 52-week low of $0.73 and a 52-week high of $11.90. The company has a market cap of $16.01 million, a P/E ratio of -0.15 and a beta of 0.52.

Institutional Investors Weigh In On Accelerate Diagnostics

A number of hedge funds and other institutional investors have recently modified their holdings of AXDX. Virtu Financial LLC raised its position in Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 17,461 shares during the last quarter. Bank of Montreal Can bought a new position in Accelerate Diagnostics during the 1st quarter valued at approximately $27,000. Cubist Systematic Strategies LLC bought a new position in Accelerate Diagnostics during the 3rd quarter valued at approximately $29,000. Bank of America Corp DE raised its position in Accelerate Diagnostics by 110.7% during the 4th quarter. Bank of America Corp DE now owns 42,395 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 22,273 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Accelerate Diagnostics by 6,250.0% in the 1st quarter. UBS Group AG now owns 50,800 shares of the medical research company’s stock worth $36,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors own 17.14% of the company’s stock.

Wall Street Analyst Weigh In

AXDX has been the topic of several research reports. Craig Hallum lowered their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Monday, April 1st. William Blair restated an “outperform” rating on shares of Accelerate Diagnostics in a research note on Tuesday, April 2nd. Finally, StockNews.com initiated coverage on Accelerate Diagnostics in a research note on Friday, April 12th. They issued a “hold” rating on the stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.